冠昊生物
(300238)
| 流通市值：25.24亿 | | | 总市值：25.24亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 91,441,252.36 | 404,178,697.25 | 308,949,013.47 | 210,814,871.09 |
| 营业收入 | 91,441,252.36 | 404,178,697.25 | 308,949,013.47 | 210,814,871.09 |
| 二、营业总成本 | 71,751,172.33 | 360,489,232.61 | 258,011,428.97 | 178,230,785.37 |
| 营业成本 | 20,070,872.09 | 84,366,507.09 | 60,492,760.41 | 47,231,514.11 |
| 税金及附加 | 853,805.68 | 4,367,281.13 | 3,126,318.09 | 2,149,923.09 |
| 销售费用 | 30,734,582.38 | 166,536,462.51 | 124,263,910.25 | 82,819,956.62 |
| 管理费用 | 12,473,774.86 | 55,366,142.27 | 37,204,507.36 | 23,711,909.95 |
| 研发费用 | 7,484,200.53 | 44,503,865.82 | 30,545,444.76 | 20,208,810.36 |
| 财务费用 | 133,936.79 | 5,348,973.79 | 2,378,488.1 | 2,108,671.24 |
| 其中:利息费用 | 159,791.67 | 1,782,364.35 | 1,391,084.08 | 1,019,107.91 |
| 其中:利息收入 | 130,992.97 | 1,502,794.74 | 1,148,471.09 | 761,848.52 |
| 加:投资收益 | -129,015.63 | -3,640,197.33 | -3,545,128.16 | -2,106,072.44 |
| 资产处置收益 | 1,090 | 924,105.58 | -5,019.56 | -5,019.56 |
| 资产减值损失(新) | 264,385.52 | -3,890,692.8 | -3,273,656.61 | 2,359,867.66 |
| 信用减值损失(新) | -524,388.33 | -9,278,234.44 | -4,675,356.53 | -2,972,586.96 |
| 其他收益 | 1,218,321.8 | 6,184,116.15 | 4,915,968.74 | 3,989,762.01 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 20,520,473.39 | 33,988,561.8 | 44,354,392.38 | 33,850,036.43 |
| 加:营业外收入 | 270.15 | 11,171.24 | 100,962.23 | 96,516.99 |
| 减:营业外支出 | 40,325.66 | 1,910,538.58 | 472,338.12 | 52,938.19 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 20,480,417.88 | 32,089,194.46 | 43,983,016.49 | 33,893,615.23 |
| 减:所得税费用 | 5,005,638.04 | 11,016,656.94 | 5,850,031.94 | 3,687,741.47 |
| 六、净利润 | 15,474,779.84 | 21,072,537.52 | 38,132,984.55 | 30,205,873.76 |
| 持续经营净利润 | 15,474,779.84 | 21,072,537.52 | 38,132,984.55 | 30,205,873.76 |
| 归属于母公司股东的净利润 | 14,391,514.75 | 31,005,798.58 | 41,271,327.27 | 30,743,377.17 |
| 少数股东损益 | 1,083,265.09 | -9,933,261.06 | -3,138,342.72 | -537,503.41 |
| (一)基本每股收益 | 0.05 | 0.12 | 0.16 | 0.12 |
| (二)稀释每股收益 | 0.05 | 0.12 | 0.16 | 0.12 |
| 八、其他综合收益 | -80,925.93 | 4,244,210.95 | 2,670,524.54 | 1,215,900.12 |
| 归属于母公司股东的其他综合收益 | -80,925.93 | 4,244,210.95 | 2,670,524.54 | 1,215,900.12 |
| 九、综合收益总额 | 15,393,853.91 | 25,316,748.47 | 40,803,509.09 | 31,421,773.88 |
| 归属于母公司股东的综合收益总额 | 14,310,588.82 | 35,250,009.53 | 43,941,851.81 | 31,959,277.29 |
| 归属于少数股东的综合收益总额 | 1,083,265.09 | -9,933,261.06 | -3,138,342.72 | -537,503.41 |
| 公告日期 | 2024-04-26 | 2024-03-06 | 2023-10-25 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |